Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA

Despite facing one-year delay, Coherus is buoyed by FDA’s apparent support for its decision not to conduct clinical study in cancer patients; agency requests company develop more sensitive immunogenicity assay and reanalyze subset of samples from study conducted in healthy subjects.

FDA entrance sign 2016

US licensure of Coherus BioSciences Inc.’s pegfilgrastim biosimilar is likely to be delayed at least a year following FDA’s request that the company reanalyze clinical immunogenicity data with a new, more sensitive assay.

On June 12, Coherus announced receipt of an FDA complete response letter for CHS-1701, a proposed biosimilar to Amgen...

More from Biosimilars

More from Biosimilars & Generics